Press Releases

NEW YORK , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso , President and Chief

Jerry Durso Appointed CEO Effective January 1, 2021 ; Founder, President and CEO Mark Pruzansk i to Continue as Board Member   and Advis o r NEW YORK , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and

NEW YORK , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski , M.D., President and

Multiple new analyses reinforce the clinical value of noninvasive strategies to identify and monitor patients with advanced fibrosis due to NASH NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and

Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over the prior year quarter Intercept updates 2020 Ocaliva Net Sales Guidance to narrow the range to $310 million to $320 million Intercept updates 2020 non-GAAP Adjusted Operating Expenses Guidance to

NEW YORK , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2020 financial results prior

Presentation of l ong -term   efficacy and   safety data of obeticholic acid (OCA )   for the treatment of patients with PBC A nalys i s from Phase 3 REGENERATE study examines the antifibrotic efficacy of   OCA on noninvasive measures of liver fibrosis   in patients with fibrosis due to NASH NEW

NEW YORK , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski , M.D., President and

NEW YORK , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional data indicating that obeticholic

New analyses of the interim analysis data from the Phase 3 REGENERATE study describe the benefit of obeticholic acid (OCA) on noninvasive measures of liver fibrosis   in NASH patients on treatment for at least 24 months Additional long-term data in PBC highlight the safety and durable efficacy of